A truly shocking case study, which demonstrates once again how even terminal disease are often curable with cheap, safe, and widely available compounds that have long ago been written off as “obsolete” by mainstream medicine. More importantly, the case study highlights the core role metabolism and major metabolic modulators such as serotonin (5-HT) play in virtually all chronic degenerative and even terminal diseases. Oh, and lest I forget – unlike other cancer studies so far that have used cyproheptadine as an add-on to mainstream cytotoxic treatments, in this case the 5-HT/H1 antagonist cyproheptadine was the only therapy administered.
“…A 62-year-old woman with suspected advanced HCC accompanied by bone metastasis with severe back pain and sciatica showed disease remission after cyproheptadine monotherapy. Initially, her serum alpha fetal protein (AFP) level was high, reaching up to 17697.62 ng/ml. A dose of 4 mg cyproheptadine, 3 times a day for 17 months was prescribed as the only treatment. Within 3 months, the serum AFP level gradually normalized down to 4.3 ng/ml. Both liver biopsy and bone biopsies were subsequently performed after 2 weeks of cyproheptadine. The results showed no malignancy. During the 34 months of follow-ups, the serum AFP remained normal in the range of 1.05 to 2.86 ng/ml. The patient has survived for 5 years without back pain and sciatica thus far.”
“…In this case, we prescribed only cyproheptadine based on our prior analysis of its anti-cancer properties (3, 7); it may stimulate the immune system; it may suppress prolactin, growth hormone and cortisol; thalidomide was not added at that time due to precautions of its possible adverse side effects. One tablet of cyproheptadine is 4 mg; A dose of 4 mg thrice daily is commonly recommended for colds and allergies, and it demonstrates being safe yet effective on HCC patients based on our previous report (3). Because the patient responded well to the single drug therapy while we were waiting for the results of biopsies, we decided to continue it. Because the patient’s immune system responded well to the single drug therapy while we were waiting for the results of biopsies, we decided to continue it. After three months, the results of her blood test (e.g. AFP level) and CT scan (e.g. tumor) all returned normal ranges. However, the results of CT scan still showed traces of suspected tumors. To avoid recurrence, we continued the same therapy for another fourteen months until there were no more traces of suspicious tumors, tests and symptoms.”
“…We are certain that this is not a case of spontaneous regression of HCC. The patient did not receive other type of anti-cancer therapy before or after cyproheptadine monotherapy; her symptoms vanished, and the HCC had nearly complete remission while she was treated continuously with cyproheptadine monotherapy.”